Perspective Therapeutics, Inc. Common Stock CATX 深 沪
等待开盘 10-22 09:30:00 美东时间
3.195
+0.005
+0.16%
华盛通- 最 高3.4596
- 今 开3.27
- 成交量 186.22万股
- 最 低 2.90
- 昨 收 3.19
- 总市值 2.37亿
- 52周最高 12.90
- 市盈率 静 --
- 换手率 2.51%
- 52周最低 1.60
- 委 比 -28.57%
- 总股本 7426.30万
- 历史最高 37.90
- 量 比 1.14
- 振 幅 17.54%
- 历史最低 1.60
- 每 手 1
- 风险率 4.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) shares rose 119.1% to $9.86 during Monda...
10-21 02:39
Perspective Therapeutics Reports 44% Confirmed Response Rate And 87.5% Progression-Free Patients Treated With [212Pb]VMT-α-NET At ESMO Congress 2025
Updated interim results with an additional ~19 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-toleratedObjective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression
10-20 16:34
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
BTIG Initiates Coverage On Perspective Therapeutics with Buy Rating, Announces Price Target of $14
BTIG analyst Jeet Mukherjee initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Buy rating and announces Price Target of $14.
10-10 18:26
Perspective Therapeutics Announces First Patient Treated With PSV359 In Second Cohort Of Phase 1/2a Dose-Finding Trial To Determine Safety And Preliminary Anti-Tumor Activity
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced that the first
10-02 19:03
Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
Perspective Therapeutics, Inc. has initiated a Phase 1/2a trial with [<sup>212</sup>Pb]PSV359, a radiopharmaceutical targeting solid tumors expressing FAP-α. The second cohort began dosing patients at 5.0 mCi, following a Safety Monitoring Committee recommendation based on initial 2.5 mCi results. FAP-α is prevalent in various cancers, including pancreatic, colorectal, and sarcomas, contributing to disease progression. The study aims to determine...
10-02 11:00
Perspective Therapeutics Updates Radiopharmaceutical Advancements
Perspective Therapeutics ( ($CATX) ) just unveiled an update. On October 1, 202...
10-01 19:49
美股大行评级 | 潜在涨幅302.68%！Maxim Group上调T Stamp目标价至12美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持T Stamp"买入"评级，目标价从8美元升至12美元；Maxim Group：维持Rezolute"买入"评级，目标价从15美元升至20美元
09-22 18:44
Perspective Therapeutics Says First Patient Dosed In New Cohort Of Phase 1/2a Trial Evaluating The Safety Of [212Pb]VMT01
First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-openedSEATTLE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics,
09-15 19:08
